Glenn's mailing address filed with the SEC is C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SUITE 22, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 16 years, insiders at Portola Pharmaceuticals have traded over $63,947,373 worth of Portola Pharmaceuticals stock and bought 4,311,442 units worth $137,660,828 . The most active insiders traders include (Mauritius) Pte Ltd Cairnhi..., James N Topper oraz Jeffrey W Bird. On average, Portola Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $1,543,350. The most recent stock trade was executed by Hollings Renton on 1 November 2019, trading 5,000 units of PTLA stock currently worth $45,000.
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
Portola Pharmaceuticals executives and other stock owners filed with the SEC include: